1Wald, DS, Law, M & Morris, JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202–1206.
2Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015–2022.
3Bautista, LE, Arenas, IA, Penuela, A, et al. (2002) Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 55, 882–887.
4Dayal, S & Lentz, SR (2008) Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 28, 1596–1605.
5Toole, JF, Malinow, MR, Chambless, LE, et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565–575.
6Bønaa, KH, Njølstad, I, Ueland, PM, et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578–1588.
7Lonn, E, Yusuf, S, Arnold, MJ, et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567–1577.
8Yang, Q, Botto, LD, Erickson, JD, et al. (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113, 1335–1343.
9Wang, X, Qin, X, Demirtas, H, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876–1882.
10Spence, JD (2006) Homocysteine. Call off the funeral. Stroke 37, 282–283.
11Holven, KB, Aukrust, P, Holm, T, et al. (2002) Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 22, 699–703.
12Holven, KB, Aukrust, P, Retterstøl, K, et al. (2006) Increased levels of high-sensitivity C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 66, 45–54.
13Holven, KB, Halvorsen, B, Bjerkeli, V, et al. (2006) Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects. Stroke 37, 1731–1736.
14Arnadottir, M, Hultberg, B, Nilsson-Ehle, P, et al. (1996) The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56, 41–46.
15Lewerin, C, Ljungman, S & Nilsson-Ehle, H (2007) Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly. J Intern Med 261, 65–67.
16Liu, J, Sukhova, GK, Sun, JS, et al. (2004) Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24, 1359–1366.
17Sukhova, GK, Wang, B, Libby, P, et al. (2005) Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 96, 368–375.
18Bengtsson, E, Nilsson, J & Jovinge, S (2008) Cystatin C and cathepsins in cardiovascular disease. Front Biosci 13, 5780–5786.
19Shi, GP, Sukhova, GK, Grubb, A, et al. (1999) Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104, 1191–1197.
20Albert, MA, Rifai, N & Ridker, PM (2001) Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med 6, 145–149.
21Djoussé, L, Kurth, T & Gaziano, JM (2008) Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 155, 82–86.
22Koenig, W, Twardella, D, Brenner, H, et al. (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51, 321–327.
23Ni, L, Lü, J, Hou, LB, et al. (2007) Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 38, 3287–3288.
24Maahs, DM, Ogden, LG, Kretowski, A, et al. (2007) Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 56, 2774–2779.
25Arpegård, J, Ostergren, J, de Faire, U, et al. (2008) Cystatin C – a marker of peripheral atherosclerotic disease? Atherosclerosis 199, 397–401.
26Bökenkamp, A, Herget-Rosenthal, S & Bökenkamp, R (2008) Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 21, 1223–1230.
27Nenseter, MS, Ueland, T, Retterstøl, K, et al. (2009) Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects. Effect of treatment with B-vitamins. Stroke 40, 241–247.
28Holven, KB, Halvorsen, B, Schulz, H, et al. (2003) Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects. Eur J Clin Invest 33, 555–560.
29Bengtsson, E, To, F, Grubb, A, et al. (2005) Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 180, 45–53.
30Yap, S, Boers, GH, Wilcken, B, et al. (2001) Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 21, 2080–2085.
31Keller, C, Katz, R, Cushman, M, et al. (2008) Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 9, 9.
32Keller, CR, Odden, MC, Fried, LF, et al. (2007) Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 71, 239–244.
33Singh, D, Whooley, MA, Ix, JH, et al. (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 22, 1087–1092.
34Potter, K, Hankey, GJ, Green, DJ, et al. (2008) Homocysteine or renal impairment: which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol 28, 1158–1164.